The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis

T. A. Klamer · M. Linschoten · F. W. Asselbergs

Accepted: 24 February 2022 / Published online: 9 March 2022 © The Author(s) 2022

Abstract Vaccines against coronavirus 2019 disease (COVID-19) have shown to be greatly effective in preventing viral spread, serious illness and death from this infectious disease and are therefore critical for the management of the COVID-19 pandemic. However, the listing of myocarditis and pericarditis as possible rare side effects of the messenger RNA (mRNA) vaccines against COVID-19 by regulatory agencies has sparked discussion on the vaccines’ safety. The most important published cohort studies to date demonstrate that myocarditis is a very rare side effect after COVID-19 mRNA vaccination, with an incidence of approximately 1–4 cases per 100,000 vaccinated persons. Young males (16–29 years) appear to be at highest risk, predominantly after receiving the second dose. The disease course is self-limiting in a vast majority of cases: 95% of patients show a rapid resolution of symptoms and normalisation of cardiac biomarkers, electro- and echocardiographic findings within days. Importantly, the available data suggest that the incidence rate of myocarditis in the context of COVID-19 is much greater than the risk of this side effect following vaccination. We conclude that the benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis in both adolescents and adults. Prospective follow-up of patients who have developed these complications after vaccination is required to assess long-term outcomes.

Keywords COVID-19 · COVID-19 vaccination · Coronavirus disease 2019 · Myocarditis · Pericarditis · Side effect

Introduction

In the summer of 2021, six months after the Emergency Use Authorization of the messenger RNA (mRNA) vaccines against coronavirus 2019 disease (COVID-19) from Pfizer-BioNTech and Moderna, the European Medicines Agency (EMA) and the American Food and Drug Administration (FDA) recommended listing myocarditis and pericarditis as new side effects [1, 2]. Prior to this recommendation, a number of cases of myocarditis and pericarditis had been reported in the scientific literature, as well as in the Vaccine Adverse Event Reporting System and Eu-draVigilance databases [1–4]. After reviewing the available data, both the EMA and FDA concluded that the benefit of vaccination outweighs the risk of myocarditis and pericarditis and therefore soon advised to continue the vaccination programme in the beginning of July 2021 [1–3]. However, both regulatory authorities also recommended vigilance.

New data on the occurrence of these side effects has recently appeared [5–10], reigniting the discussion on the safety of COVID-19 vaccines, especially on social media. In this point of view paper, we summarise the findings of the most important peer-reviewed population studies published thus far on the occurrence of myocarditis and pericarditis after COVID-19 vaccination, to assess whether the benefit of vaccination outweighs the possible risk of these adverse events.
Table 1  Incidence (rate) of myocarditis after COVID-19 vaccination based on data from published large population cohort studies

| Age category | Vaccine type | Male | Female | Incidence per 100,000 doses administered (95% CI) | Incidence per 100,000 vaccinated persons (95% CI) |
|--------------|--------------|------|--------|-------------------------------------------------|-----------------------------------------------|
|              | Both doses   | First dose | Second dose | First dose | Second dose | First dose | Second dose |
| 16–19 years  | Both doses   | 1.3 (0.6–2.2) | 15.1 (6.2–24.1) | 0.0 (0.0–0.1) | 0.3 (0.0–0.5) | 1.0 (0.4–1.0) | 0.6 (0.4–1.0) |
| 20–24 years  | Both doses   | 1.9 (0.5–1.0) | 10.9 (3.7–17.8) | 0.0 (0.0–0.1) | 0.2 (0.0–0.5) | 2.2 (0.0–0.5) | 1.1 (0.2–3.1) |
| 25–29 years  | NA           | 0.4 (0.0–0.9) | 7.0 (2.0–13.9) | 0.0 (0.0–0.1) | 0.2 (0.0–0.5) | 0.0 (0.0–0.1) | 0.2 (0.0–0.5) |
| 30–39 years  | NA           | 0.6 (0.0–1.0) | 3.7 (0.8–6.5) | 0.0 (0.0–0.1) | 0.2 (0.0–0.5) | 0.1 (0.0–0.2) | 0.1 (0.0–0.2) |
| 40–49 years  | NA           | 0.0 (0.0–0.1) | 1.9 (0.0–0.3) | 0.0 (0.0–0.1) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) | 0.0 (0.0–0.1) |
| 50–59 years  | NA           | 0.0 (0.0–0.1) | 0.7 (0.0–1.7) | 0.0 (0.0–0.1) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) | 0.0 (0.0–0.1) |
| 60–69 years  | NA           | 0.1 (0.0–0.3) | 1.2 (0.0–2.7) | 0.0 (0.0–0.1) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) | 0.0 (0.0–0.1) |
| 70–79 years  | NA           | 0.1 (0.0–0.3) | 0.7 (0.1–1.5) | 0.0 (0.0–0.1) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) | 0.0 (0.0–0.1) |
| 80+ years    | NA           | 0.1 (0.0–0.3) | 0.7 (0.1–1.5) | 0.0 (0.0–0.1) | 0.1 (0.0–0.2) | 0.0 (0.0–0.1) | 0.0 (0.0–0.1) |

Notes:
- Incidence per 100,000 vaccinated persons (95% confidence interval (CI) not available) within 21 days after first and second vaccine dose; interval between first and second dose: 21 days.
- Incidence per 100,000 doses administered (95% CI) within 7 days after first and second vaccine dose; interval between first and second dose: 21 days.
- Incidence per 100,000 vaccinated persons (95% CI) within 28 days after first or second vaccine dose; median interval between first and second dose: 35 days.
- Incidence per 100,000 doses administered (95% CI) within 7 days after first and second vaccine dose; interval between first and second dose: not available. Since original results were calculated per 1,000,000 doses administered, the incidence was divided by ten to calculate the incidence per 100,000 doses administered.
- Incidence per 100,000 vaccinated persons (95% CI) within 14 days after first and second vaccine dose; interval between first and second dose: not available.

Pfizer-BioNTech vaccine Comirnaty, Moderna vaccine Spikevax, NA not available.
Vaccines are the most critical tool in efforts to control the COVID-19 pandemic. The dramatic impact of the pandemic accelerated the development and approval of two mRNA vaccines: Comirnaty from Pfizer-BioNTech and Spikevax from Moderna [22–24]. After the start of the vaccination campaign in Israel, its Ministry of Health started active surveillance of myocarditis in February 2021 following early reports on the occurrence of myocarditis as a possible adverse side effect [6]. The first case series in the literature appeared three months later and described three young male patients who had been diagnosed with myocarditis two days after the second dose of the Pfizer-BioNTech vaccine [25].

The pathophysiological mechanisms behind the development of myocarditis and pericarditis after a COVID-19 vaccination are currently not completely understood. One hypothesis is that the immune system detects the mRNA molecules as antigens, triggering an immune reaction in certain individuals [4, 26]. Another mechanism that has been proposed is that antibodies against a part of the SARS-CoV-2’s spike protein that the mRNA encodes for, cross-react with structural similar host proteins in the heart, also known as molecular mimicry [27]. Similar mechanisms have been described for the occurrence of neurological phenomena after vaccination against COVID-19, including transverse myelitis [28].

The first large population cohort studies that were conducted in Israel provided more insight into the overall incidence of myocarditis after COVID-19 vaccination. Mevorach et al. used the database of the Israeli Ministry of Health to assess the occurrence of myocarditis from December 2020 until May 2021 [6]. Over 9 million Israeli residents were included, of whom more than 5.4 million had received at least one dose of the Pfizer-BioNTech vaccine. Possible cases were identified based on the International Classification of Diseases, Ninth Revision (ICD-9) codes for myocarditis and reviewed case by case to determine the likelihood of the diagnosis. In total, 136 patients were diagnosed with definite or probable myocarditis, mainly within proximity of the second vaccination, corresponding with an overall cumulative incidence of 3.83 per 100,000 in males and 0.46 per 100,000 in females. The highest incidence was found in males aged 16–19 years, equaling an incidence of 15.07 per 100,000 young males (Tab. 1) [6]. The age- and sex-adjusted standardised incidence ratio for myocarditis between those that had received a second dose compared with a pre-pandemic cohort was 5.34 (95% CI 4.48–6.40). This difference was mainly driven by young male vaccine recipients (16–19 years of age), in whom the standardised incidence ratio was 13.60 (95% CI 9.30–19.20). The standardised incidence ratio after the first dose was 1.42 (95% CI 0.92–2.10) for the whole population and 1.62 (95% CI 0.32–4.72) for young males (16–19 years). Of the identified 136 cases, 129 (94.9%) had a mild disease course defined as a resolution of symptoms within days with normalisation of cardiac biomarkers and any abnormalities detected with ECG and echocardiography. In one case (0.7%), myocarditis was fulminant and led to death [6].

The second Israeli study used comparable methods and searched for cases in the database of Clalit Health Services, the largest health care organisation of Israel providing care to 4.7 million Israeli residents [7]. The occurrence of myocarditis in this cohort was similar to that in the study of Mevorach et al. [6], with an overall cumulative incidence of 2.13 per 100,000 persons [7]. Again, myocarditis was most often observed in young males aged 16–29 years (10.69 cases per 100,000 vaccinated persons) (Tab. 1). Overall, almost all cases (53/54, 98.1%) were classified as mild or moderate [7, 13]. Left ventricular dysfunction was detected in 29% of the patients diagnosed with myocarditis. Two-thirds of patients were discharged from hospital without ongoing medical treatment, and cardiac function had normalised in all patients who underwent additional testing after discharge. Only one patient developed fulminant myocarditis leading to cardiogenic shock.

Husby et al. evaluated data from the entire Danish population, comprising almost 5 million individuals, by linking the Danish Vaccination Register to hospital-based diagnoses from the Danish National Patient Register [5]. The primary outcome measure of this study was defined as a myocarditis and/or pericarditis diagnosis (according to the ICD-10 codes) with
Advertisement placed here.
Fig. 1 COVID-19-vaccine related myocarditis. a Typical characteristics of individuals developing myocarditis after COVID-19 mRNA vaccination. Studies showed a marked age and sex difference: incidence of myocarditis is 5.0–17.5 times higher in young males aged 16–29 years [5–10]. Myocarditis mainly occurs after second vaccine dose [6–8]. b Number of patients with a mild/moderate, fulminant or unknown disease course of myocarditis; frequencies were calculated based on two studies that reported these data [6, 7]. c Clinical myocarditis after COVID-19 vaccination was most often diagnosed within 14–30 days after the first or second dose. For comparative purposes, annual incidence of myocarditis prior to the COVID-19 pandemic was assumed to be evenly spread each year, with overall annual incidence of 16 cases per 100,000 persons [11], which equals 1.3 cases per 100,000 persons per month. Based on joint data from CAPACITY-COVID registry and Lean European Open Survey on SARS-CoV-2 (LEOSS), 37 of 16,368 SARS-CoV-2 infected patients were diagnosed with myocarditis during median length of hospital stay of 9 days (interquartile range 5–18) [16]. Of 1597 competitive athletes screened for safe return to play after COVID-19, 5 were diagnosed with clinical myocarditis (cardiac symptoms present at the time of cardiac testing) 13–77 days after the infection [18]. d Estimated benefit of COVID-19 mRNA vaccination in young males (12–17 years) in England in April 2021 (low incidence of SARS-CoV-2 infection) and July 2021 (high incidence of SARS-CoV-2 infection).
The benefits of vaccination against COVID-19 outweigh the potential risk of myocarditis and pericarditis.

The benefits of the COVID-19 mRNA vaccines clearly outweigh the slim risks of myocarditis and pericarditis, with an overall cumulative incidence of 0.6–4 and 0–2 per 100,000 vaccinated persons for males and females, respectively. Prospective studies evaluating long-term outcomes in patients who have developed these complications, as well as the safety of administering a subsequent COVID-19 mRNA vaccine dose, are still warranted.

**Funding** CAPACITY-COVID is supported by the Dutch Heart Foundation (Hartstichting) (2020B006 CAPACITY), Netherlands Organisation for Health Research and Development (ZonMw) (DEFENCE 10430102110006), EuroQol Research Foundation, Novartis Global, Sanofi Genzyme Europe, Novo Nordisk Nederland, Servier Nederland and Daiichi Sankyo Nederland. M. Linschoten is supported by the Alexandre Suerman Stipend of the University Medical Centre Utrecht. E.W. Asselbergs is supported by the National Institute of Health Research University College London Hospitals Biomedical Research Centre.

**Conflict of interest** T.A. Klamer, M. Linschoten and E.W. Asselbergs declare that they have no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**Point of View**

the co-occurrence of troponin release and a length of hospital stay of at least one day. The association between COVID-19 vaccination and cardiac arrest or death was a secondary outcome measure. Among vaccinated individuals in Denmark (84.3% of the population), 83.8% were vaccinated with Comirnaty (Pfizer-BioNTech) and 12.0% with Spikevax (Moderna). The incidence rate of myocarditis was 1.7 per 100,000 vaccinated persons (n=269 cases). Those vaccinated with Spikevax had a statistically significantly higher risk of myocarditis during follow-up than unvaccinated individuals (hazard ratio (HR) 3.92, 95% CI 2.30–6.68), especially among individuals aged 12–39 years (HR 5.24, 95% CI 2.47–11.12). Similar findings were reported by Patone et al. [10]. In line with the Israeli studies, myocarditis was diagnosed more frequently in men (73%) in the Danish population [5]. Of the myocarditis patients, 40% were aged 12–39 years, and the clinical outcomes after myocarditis were generally described as mild without any readmissions or the occurrence of heart failure or death within 28 days after vaccination. Importantly, individuals vaccinated with either mRNA vaccine had a markedly reduced risk of cardiac arrest or death compared with unvaccinated individuals.

The findings of five large cohort studies [5–9] and four publicly-accessible databases collecting data on adverse events after vaccination [29–31] are summarised in Tab. 1 and 2, respectively. Typical characteristics of patients diagnosed with myocarditis after mRNA vaccination and a comparison of the incidence of clinical myocarditis prior to the pandemic in patients with COVID-19 and after COVID-19 mRNA vaccination are visualised in Fig. 1.

**Risks versus benefits**

Being aware of the risks of myocarditis and peri-carditis following COVID-19 mRNA vaccination, do the benefits of vaccination outweigh these risks, especially in young males? According to an analysis conducted by the CDC, administering a million sec-ond doses of an mRNA vaccine in males aged 12–17 prevents 5700 COVID-19 cases, 215 hospitalisations, 71 admissions to the intensive care unit and 2 deaths over a period of 17 weeks [32]. Not surprisingly, the benefit of the vaccines in older patients is even larger. Similar estimations were computed in England (Fig. 1d) [33].

Furthermore, in a study by Barda et al., the risk ratio of myocarditis in the context of a SARS-CoV-2 infection was estimated to be 18.28 (95% CI 3.95–25.12) compared with the uninfected group, which corre-sponds with a risk difference of 10.96 events per 100,000 patients (95% CI 5.57–15.80) [34]. This illustrates that the incidence of myocarditis in the context of COVID-19 is much greater than the risk of this side effect following COVID-19 vaccination.

**Conclusion**

The benefits of the COVID-19 mRNA vaccines clearly outweigh the slim risks of myocarditis and pericarditis, with an overall cumulative incidence of 0.6–4 and 0–2 per 100,000 vaccinated persons for males and females, respectively. Prospective studies evaluating long-term outcomes in patients who have developed these complications, as well as the safety of administering a subsequent COVID-19 mRNA vaccine dose, are still warranted.

**References**

1. European Medicines Agency. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericardi-tis. www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis. Accessed 26 Jan 2022.
2. Food and Drug Agency. Coronavirus (COVID-19) Up-date: June 25, 2021. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021. Accessed 26 Jan 2022.
3. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently ap-proved or authorized in the United States. www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html. Accessed 26 Jan 2022.
4. Bozkurtt B, Kamat I, Hotz PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471–84.
5. Husby A, Hansen JV, Fosbol E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e68665.
6. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–9.

7. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132–9.

8. Chua GT, Kwan MYW, Chui CSHL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciaa899.

9. Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;32:331–40.

10. PatoneM, MeiXW, HandunnetthiL, et al. Risksofmyocardi-

11. Healthdata. Global burden of disease 2019 cause and risk summaries: myocarditis—level 4 cause. www.healthdata.org/results/gbd_summaries/2019/myocarditis-level-4-cause. Accessed 26 Jan 2022.

12. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48.

13. Sinagra G, Anzini M, Perreira NL, et al. Myocarditis in clinical practice. Mayo Clin Proc. 2016;91:1256–66.

14. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with Coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:819–24.

15. Fiore G, Sanvito F, Fragasso G, Spoladore R. Case report of cardiogenic shock in COVID-19 myocarditis: peculiarities on diagnosis, histology, and treatment. Eur Heart J Case Rep. 2021;5:ytab357.

16. Linschoten M, Uijl A, Schut A, et al. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab656.

17. Boehm TK, Kompaniets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data—United States, march 2020–January 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1228–32.

18. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol. 2021;6:1078–87.

19. Van Hattum JC, Spies JL, Verwijs SM, et al. Cardiac abnormalities in athletes after SARS-CoV-2 infection: a systematic review. BMJ Open Sport Exerc Med. 2021;7:e1164.

20. Fox SE, Falgout L, Van der Heide RS. COVID-19 myocarditis: quantitative analysis of the inflammatory infiltrate and a proposed mechanism. Cardiovasc Pathol. 2021;54:107361.

21. Caso E, Costa L, Ruscitti P, et al. Could Sars-covoravirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimm Rev. 2020;19:102524.

22. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15.

23. Baden LR, El Shaly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.

24. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–73.

25. Nevet A. Acute myocarditis associated with COVID-19 vaccination. Clin Exp Vaccine Res. 2021;10:196–7.

26. Karikó K, Buckstein M, Ni H, et al. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165–75.

27. Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. Autoimm Rev. 2020;19:102597.

28. Kaulen LD, Dubroviniskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a caseseries. Eur J Neurol. 2022;29:555–63.

29. Lareb. Overview of pericarditis and myocarditis associated with COVID-19 vaccines. www.lareb.nl/media/zsdapxpk/signals_2021_overview-of-pericarditis-and-myocarditis-associated-with-covid-vaccines.pdf. Accessed 26 Jan 2022.

30. United Kingdom Government. Information for healthcare professionals on myocarditis and pericarditis following COVID-19 vaccination. www.gov.uk/government/publications/covid-19-vaccination-myocarditis-and-periocarditis-information-for-healthcare-professionals-information-for-healthcare-professionals-on-myocarditis-and-periocarditis-following-covid-19-vaccination. Accessed 26 Jan 2022.

31. Lane S, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A review of spontaneously reported data from the UK, Europe, and the US. www.medsrxiv.org/content/10.1101/2021.09.09.21263342v2. Accessed 26 Jan 2022.

32. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–82.

33. Gurdasani D, Bhatt S, Costello A, et al. Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis. JR Soc Med. 2021;114:513–24.

34. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide Setting. N Engl J Med. 2021;385:1078–90.